Pramlintide
Also called Symlin
Subcutaneous (under the skin)Product label
Research reference
Product label
SymlinPen meal-linked schedule
Before major meals: type 1 starts at 15 mcg; type 2 starts at 60 mcg; changes at least 3 days apart
Individual glucose and nausea review—not a fixed cycle
SymlinPen product label ↗When results may show
- When change was measured
- The label requires a coordinated mealtime-insulin reduction at initiation and frequent glucose checks because severe low blood sugar can occur.
- When to assess
- Individual glucose and nausea review—not a fixed cycle
- Conditions and limitations
- Adults using mealtime insulin for type 1 or type 2 diabetes. Clinician-managed insulin changes are essential. Do not auto-start this medicine or translate meal-linked doses into fixed hourly reminders.
- When to stop
- Use the exact product's clinical monitoring and stopping instructions. A supply interval is not a stop date; severe or persistent reactions need prompt clinical review.
Sources: SymlinPen product label
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Pramlintide describe 15–120 mcg per administration. Descriptive only, not a recommendation.
Modelled level — twice a day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 4hours
- Administrations
- 14/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- SymlinPen product labelClinician-managed insulin changes are essential. Do not auto-start this medicine or translate meal-linked doses into fixed hourly reminders.
Next steps
Pramlintide beginner guideOpen Pramlintide planning worksheetEstimate Pramlintide vial costTrack Pramlintide notes